Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer
NCT07261709Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07261709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261709.